Hypoxia-adapted Multiple Myeloma Stem Cells Resist γδ-T-Cell-mediated Killing by Modulating the Mevalonate Pathway

Abstract

Background/Aim: The prognosis of patients with multiple myeloma (MM) has recently improved due to the emergence of new molecular targeting agents. However, MM remains incurable because MM stem cells are resistant to these agents. Therefore, it is essential to develop strategies to eradicate MM stem cells. We have previously demonstrated that MM cells cultured under prolonged hypoxic conditions (1% O 2 ) (i. e., hypoxia-adapted MM cells; MM-HA cells) exhibited stem-celllike characteristics. γδ T cells attack tumor cells by recognizing butyrophilin (BTN) 3A1 and BTN2A1, which are activated by the intracellular accumulation of isopentenyl pyrophosphate (IPP), an intermediate in the mevalonate pathway. In the present study, we investigated the cytotoxicity of γδ T cells against MM-HA stem-like cells. Materials and Methods: We used a combination of flow cytometry, liquid chromatography-tandem mass spectrometry, and western blotting methods to investigate the cytotoxicity of γδ T cells against MM-HA cells and measured the amounts of IPP in MM-HA cells and their supernatants.Results: The cytotoxicity of γδ T cells against MM-HA cells was significantly lower than that against MM cells cultured under normoxic conditions (20% O 2 ; MM-Normo). Furthermore, the concentration of IPP in MM-HA cells was lower than that in MM-Normo cells. The expression of mevalonate decarboxylase and farnesyl diphosphate synthase proteins were decreased in MM-HA-cells. Conclusion: The cytotoxicity of γδ T cells against MM-HA cells was suppressed by the reduced IPP accumulation by modulating the mevalonate pathway in MM-HA cells.

POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma

“…Western blot analysis. The methods for preparation of cell lysates, immunoblotting, and detection of bands corresponding to immunoreactive proteins have been described elsewhere (11). Samples were blotted with primary antibodies against the following proteins: POLD1 (#ab186407, Abcam, Cambridge, UK), GAPDH (#2118, Cell Signaling Technology, Danvers, MA, USA), phospho-histone H2A.X (Ser139) (05-636, Millipore Merck, Burlington, MA, USA), phospho-ATM (ser1981) (#5883, Cell Signaling Technology), ATM (#2873, Cell Signaling Technology), vinculin (sc-73614, Santa Cruz Biotechnology, Dallas, TX, USA), phospho-Chk2 (Thr68) (#2197, Cell Signaling Technology), Chk2 (sc-5278, Santa Cruz Biotechnology), phospho-p53 (Ser20) (#9287, Cell Signaling Technology) and p53 (sc-126, Santa Cruz Biotechnology).…”